Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: January 7, 2026
SMART Polymer Non-Steroidal Contraceptive Device
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): St. Louis College of Pharmacy, Washington University, Brigham and Women's Hospital, University of Cincinnati, Yale University
Active
Last updated: January 7, 2026
SLO3 Inhibitors

VU0546110, VU6032735

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Washington University, Vanderbilt University
Active
Last updated: January 7, 2026
SCHIELD Biodegradable Implant MPT
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): RTI International
Active
Last updated: January 7, 2026
sAC Inhibitors

TDI-11861, TDI-10229

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Weill Cornell Medicine, Sacyl Pharmaceuticals
Active
Last updated: January 7, 2026
Refillable Nanofluidic Subcutaneous Implant

ENG + ISL NanoMPI

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Washington, Methodist Hospital Research Institute
Active
Last updated: January 7, 2026
Progestin Microarray Patch
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intradermal
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Cardiff University, InnoCore Pharmaceuticals
Active
Last updated: January 7, 2026
On Demand Oral UPA + Meloxicam
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Pericoital
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Stanford University
Active
Last updated: January 7, 2026
On Demand Oral Levonorgestrel
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Oral
  • Intended Duration: Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): FHI 360, HRA Pharma, Gynuity Health Projects, Population Council, PATH
Active
Last updated: January 7, 2026
Peptide 17BIPHE2

LL-37, Truncated Forms GI-20 and GF-17

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Ottawa Hospital Research Institute (OHRI)
Active
Last updated: January 7, 2026
Oleanolic Acid
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Short-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): South African Medical Research Council, University of Western Cape, University of Missouri